Skip to main content
. 2022 Dec 3;14(12):2710. doi: 10.3390/pharmaceutics14122710

Figure 4.

Figure 4

Assessment of cGAS-STING axis activation by Ara-C/DS and its components. Presented are immunoblots of P-TBK1, P-IRF3, P-STING, and GAPDH in (A) colorectal cells cell lines (HT-29 & HCT 116), (B) ovarian cancer cell lines (A2780 & A2780R), and (C) immunological cells (THP-1 derived macrophages & PBMC) after treatment for 6 h with standard dose Ara-C/DS (50 nM Ara-C, 1 µg/mL DS), high dose Ara-C (2.5 µM), high dose DS (50 µg/mL), the high dose Ara-C/DS combination (2.5 µM Ara-C, 50 µg/mL DS), or the cGAMP STING agonist (1 µg/mL) as a positive control. Results shown are representative of three replicate experiments. NT = non-treated. Densitometry values have been normalized to the GAPDH loading control, and are relative to the NT control. The uncropped bolts are shown in Supplementary Materials.